drugset / Trial / NCT04694300

OTC Naproxen and Acetaminophen Anti-Inflammatory Action in Dental Implant Patients

NCT04694300 ↗

RandomizedParallel-groupQuadruple-blindBasic science

Summary

This double-blind pilot study will evaluate the anti-inflammatory and analgesic effects of an over-the-counter (OTC) regimen of naproxen sodium versus acetaminophen in patients receiving one or two (adjacent) dental implants. It will also confirm that naproxen sodium in the OTC dosage range is a good alternative to immediate-release opioid formulations, which are subject to misuse, abuse and diversion in this patient population.

Timeline

Start
2021-02-07
Primary completion
2022-08-28
Completion
2022-08-28

Outcome

Mixed primary results

registry MEDIAN Naproxen Sodium: 1 (0 to 2.0) score on a scale NCT04694300 ↗

registry MEDIAN Acetaminophen: 3 (2.0 to 7.0) score on a scale NCT04694300 ↗

registry analysis (superiority test); Naproxen Sodium vs Acetaminophen; p <0.05; Wilcoxon (Mann-Whitney) NCT04694300 ↗

registry MEAN Naproxen Sodium: 0.3 (0 to 0.6) units on pain intensity scale NCT04694300 ↗

registry MEAN Acetaminophen: 1.7 (0.3 to 3.2) units on pain intensity scale NCT04694300 ↗

paper Pain scores were significantly lower in patients treated with naproxen sodium compared to those treated with acetaminophen. PMID 37266144 ↗

registry MEDIAN Naproxen Sodium: 6.5 (6.1 to 13.4) pg/ml NCT04694300 ↗

registry MEDIAN Acetaminophen: 12.1 (6.7 to 30.0) pg/ml NCT04694300 ↗

registry analysis (superiority test); Naproxen Sodium vs Acetaminophen; p = 0.12; Wilcoxon (Mann-Whitney) NCT04694300 ↗

registry MEDIAN Naproxen Sodium: 276.9 (181.3 to 348.4) percentage change from baseline NCT04694300 ↗

registry MEDIAN Acetaminophen: 519.1 (262.6 to 1091) percentage change from baseline NCT04694300 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acetaminophen Small molecule 1000 mg Oral
Subject Naproxen Small molecule 220 mg Oral
Background Tramadol Other / unclassified 50 mg —

Indications

No indication recorded.